To evaluate progression-free survival (PFS) in patients with survivin positive newly diagnosed glioblastoma multiforme (GBM) treated with SurVaxM and standard of care temozolomide. PFS is defined as the time from date of diagnosis to the date of first observed disease progression or death due to any cause.
This phase II trial studies the side effects and how well vaccine therapy works when given together with temozolomide in treating patients with newly diagnosed glioblastoma. Vaccines made from the survivin peptide or antigen may help the body build an effective immune response to kill tumor cells that express survivin. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether temozolomide is more effective with or without vaccine therapy in treating glioblastoma.